A Phase II, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)

Trial Profile

A Phase II, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Autologous cultured kidney tissue cells (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors RegenMedTX
  • Most Recent Events

    • 07 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 03 Mar 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
    • 03 Mar 2018 Planned primary completion date changed from 1 Oct 2020 to 1 May 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top